Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Journey Medical (DERM) FCF Margin: 2020-2025

Historic FCF Margin for Journey Medical (DERM) over the last 5 years, with Sep 2025 value amounting to -13.52%.

  • Journey Medical's FCF Margin fell 561.00% to -13.52% in Q3 2025 from the same period last year, while for Sep 2025 it was -6.62%, marking a year-over-year increase of 4163.00%. This contributed to the annual value of -42.98% for FY2024, which is 4328.00% down from last year.
  • Per Journey Medical's latest filing, its FCF Margin stood at -13.52% for Q3 2025, which was down 115.35% from -6.28% recorded in Q2 2025.
  • Over the past 5 years, Journey Medical's FCF Margin peaked at 54.28% during Q3 2023, and registered a low of -108.28% during Q4 2023.
  • Its 3-year average for FCF Margin is -16.90%, with a median of -13.52% in 2025.
  • In the last 5 years, Journey Medical's FCF Margin tumbled by 9,475bps in 2022 and then soared by 12,461bps in 2024.
  • Quarterly analysis of 5 years shows Journey Medical's FCF Margin stood at -18.30% in 2021, then tumbled by 572bps to -24.03% in 2022, then crashed by 8,425bps to -108.28% in 2023, then surged by 12,461bps to 16.34% in 2024, then slumped by 561bps to -13.52% in 2025.
  • Its last three reported values are -13.52% in Q3 2025, -6.28% for Q2 2025, and -21.55% during Q1 2025.